FDA gives AbbVie accelerated approval for antibody-drug conjugate in lung cancer
The FDA approved a new antibody-drug conjugate from AbbVie on Wednesday to treat patients with certain kinds of lung cancer. Regulators granted accelerated approval to telisotuzumab vedotin in second-line non-small cell lung cancer for patients ...
The FDA approved a new antibody-drug conjugate from AbbVie on Wednesday to treat patients with certain kinds of lung cancer.
Regulators granted accelerated approval to telisotuzumab vedotin in second-line non-small cell lung cancer for patients ...
